Bide Pharmatech Co., Ltd.

Bide Pharmatech Co., Ltd. faced a notable stock decline, contrasting with the broader market's performance. Despite a decrease in stock value over various timeframes, the company reported increased net sales and reduced raw material costs, alongside a favorable debtors turnover ratio and competitive valuation metrics in the pharmaceuticals sector.

Bide Pharmatech Co., Ltd. has experienced notable stock performance, significantly outperforming the China Shanghai Composite. The company reported record net sales of CNY 351.58 million and maintains a solid operational framework, with a return on equity of 6.97% and a price-to-book value of 3.56.

Bide Pharmatech Co., Ltd. saw a notable stock increase on March 24, 2026, reaching an intraday high of CNY 52.78. Despite recent declines over the past week and month, the company reported strong financial metrics, including record net sales of CNY 351.58 million and a market capitalization of CNY 2,235 million.

Bide Pharmatech Co., Ltd. faced a notable stock decline, dropping significantly on March 23, 2026. The company's performance has lagged behind the broader market over various timeframes. However, it reported positive financial metrics, including increased net sales and reduced raw material costs, maintaining an appealing valuation profile.

Bide Pharmatech Co., Ltd. saw a notable increase in its stock today, reaching an intraday high. Despite recent declines over the past week and month, the company reported strong financial results, including record net sales and improved debtors turnover, highlighting its ongoing valuation strength in the market.